Ross Summer is a Respiratory physician affiliated with Thomas Jefferson University. OpenAlex indexes 206 publications with 7,286 citations (h-index 41).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
834 Walnut St
Suite 650
Philadelphia, PA 191075109
Telephone
215-955-5161Registry record last updated 6 Nov 2012.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20256 payments
- Regeneron Healthcare Solutions, Inc.Program year20252 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
52.7%Corticosteroid28.3%Breo Ellipta41%Trelegy Ellipta34%Budesonide-Formoterol Fumarate14%Fluticasone Propionate10%Part D<11 patientsbeta2-Adrenergic Agonist18.1%Albuterol Sulfate Hfa88%Ventolin Hfa13%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
38.9%Kinase inhibitor30.5%Ofev100%Part D≥29 patientsPyridone6.5%Pirfenidone100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
8.4%Corticosteroid8.4%Prednisone100%Part D≥35 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2012–2024 per NIH RePORTER. The latest:
- Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
Thomas Jefferson University
FY2024$635,918R01HL152703 - Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
Thomas Jefferson University
FY2023$648,894R01HL152703 - Targeting Latexin Signaling for Endothelial Barrier Dysfunction in Inflammatory Lung Injury
Thomas Jefferson University
FY2023$106,080R01HL152703
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Whellan, MD
Thomas Jefferson University
Jesse Roman, MD
Thomas Jefferson University
Stephen Silberstein, MD
Thomas Jefferson University
David Cognetti, MD
Thomas Jefferson University
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”